BioPharma Dive 6 avr. 2026 Under-the-skin Tepezza comparable to infused version in key study, Amgen says
BioPharma Dive 4 févr. 2026 Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan